Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2007-04-13
2011-11-01
Vivlemore, Tracy (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S024500, C435S320100
Reexamination Certificate
active
08048863
ABSTRACT:
RNA interference is provided for inhibition of spleen tyrosine kinase (Syk) mRNA expression, in particular, for treating patients having a Syk-related inflammatory condition or at risk of developing a Syk-related inflammatory condition such as allergic conjunctivitis, ocular inflammation, dermatitis, rhinitis, asthma, allergy, or mast-cell disease.
REFERENCES:
patent: 5360720 (1994-11-01), Miller et al.
patent: 5545626 (1996-08-01), Stein et al.
patent: 2005/0075306 (2005-04-01), Schreiber et al.
patent: 2007/0141611 (2007-06-01), Khvorova et al.
patent: 2004045543 (2004-06-01), None
patent: 2005007623 (2005-01-01), None
patent: 2005049838 (2005-06-01), None
patent: 2005083083 (2005-09-01), None
patent: 2005085443 (2005-09-01), None
Miller, et al.; “Human conjunctival mast cell responses in vitro to various secretagogues”; Ocular Immunology and Inflammation; vol. 4, No. 1, pp: 39-49; 1996.
Stenton, et al.; “Inhibition of allergic inflammation in the airways using aerosolized antisense to sky kinase”; The Journal of Immunology; vol. 169; pp. 1028-1036; 2002.
Kirshenbaum, et al.; “Characterization of novel stem cell factor responsive human mast cell lines LAD 1 and 2 established from a patent with mast cell sarcoma/leukemia; activation following aggregation of FceRl or FcyRl”; Leukemia Research, vol. 27; pp. 677-682; 2003.
Altschul, et al.; “Basic local alignment search tool”; J. Mol. Biology; vol. 215; pp. 403-410; 1990.
Brummelkamp, et al; “A system for stable expression of short interfering RNAs in mammalian cells”; vol. 296; pp. 550-553; 2002.
Castanotto, et al.; “Functional siRNA expression from transfected PCR products”; RNA; vol. 8; pp. 1454-1460; 2002.
Kim, et al.; “Synthetic dsRNA dicer substrates enhance RNAi potency and efficacy”; Nature Biotechnology; vol. 23; No. 2; pp. 222-226; Feb. 2005.
Offord, et al.; “Immortalized human corneal epithelial cells for ocular toxicity and inflammation studies”; Invest. Ophthalmol Vis. Science; vol. 40; pp. 1091-1101; 1999.
Elbashir, et al.; “Functional anatomy of siRNAs for mediating efficient RNAi inDrosophila melanogasterembryo lysate”; EMBO Journal; vol. 20; No. 23; pp. 6877-6888; 2001.
Gevrey et al.; “Sky is required for monocyte/macrophase chemotaxis to CX3CL1 (fractalkine)”; Journal of Immunology; vol. 175; No. 6; pp. 3737-3745 (Sep. 6, 2005).
Takada et al.; “TNF activates Sky protein tyrosine kinase leading to TNF-induced MAPK activation, NF-KB activation, and apoptosis”; Journal of Immunology; vol. 173; No. 2; pp. 1066-1767 (Jul. 15, 2004).
Popescu; “Antisense- and RNA interference-based therapeutic strategies in allergy”; Journal of Cellular and Molecular Medicine; vol. 9; No. 4; pp. 840-853 (Oct. 1, 2005).
Chatterton Jon E.
Gamache Daniel A.
Miller Steven T.
Yanni John M.
Alcon Research, Ltd.
Derry Jason J.
Vivlemore Tracy
LandOfFree
RNAi-mediated inhibition of spleen tyrosine kinase-related... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with RNAi-mediated inhibition of spleen tyrosine kinase-related..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and RNAi-mediated inhibition of spleen tyrosine kinase-related... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4276752